Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie*
暂无分享,去创建一个
[1] J. Siewert,et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer , 1992, Cancer.
[2] R. Izumi,et al. [Ovarian epithelial tumors of borderline malignancy]. , 1992, Rinsho byori. The Japanese journal of clinical pathology.
[3] F. Jänicke,et al. Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.
[4] J. Calvete,et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.
[5] F. Jänicke,et al. [Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]. , 1991, Geburtshilfe und Frauenheilkunde.
[6] M. Schmitt,et al. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. , 1990, Blood.
[7] K. Ulm,et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .
[8] M. Cubellis,et al. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.
[9] M. Duffy,et al. Urokinase plasminogen activator and prognosis in breast cancer , 1990, The Lancet.
[10] M. Schmitt,et al. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. , 1988, Cancer research.
[11] O. Wilhelm,et al. Relation of fibrin and tumour-associated antigens to the spread of ovarian cancer , 1987 .
[12] D. Bostwick,et al. Ovarian epithelial tumors of borderline malignancy: A clinical and pathologic study of 109 cases , 1986, Cancer.
[13] H. Graeff,et al. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. , 1984, Thrombosis research.
[14] C. Griffiths,et al. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. , 1979, Cancer treatment reports.
[15] H. Abe. [CLINICAL ASPECTS OF FIBRINOLYSIS]. , 1964, Nihon Ishikai zasshi. Journal of the Japan Medical Association.